Prothrombotic factors and nonalcoholic fatty liver disease: An additional link to cardiovascular risk?
F. Barrera,J. George
DOI: https://doi.org/10.1002/hep.26588
IF: 17.298
2014-01-01
Hepatology
Abstract:O ne of the vexing questions in clinical hepatology is defining the specific and independent contribution of the liver to systemic metabolic dysregulation, defined operationally by the term metabolic syndrome. The latter comprises a spectrum of disorders including obesity, insulin resistance, hypertension, and dyslipidemia. Clarifying the conundrum is difficult, as we tend to practice in silos as hepatologists or diabetic specialists, rather than as physicians. Ideally, defining the role of the liver to cardiometabolic risk requires prospective, well-defined, large patient cohorts with baseline liver histology, determinations of fat depots, an assessment of endocrine function and insulin sensitivity, together with long-term follow-up and regular liver assessments. Nevertheless, some progress has been made. Several cross-sectional studies have described an association between the presence of nonalcoholic fatty liver disease (NAFLD) and markers of atherosclerosis such as carotid artery thickness, endothelial dysfunction, coronary artery calcification, and stenosis. Epidemiological studies have also demonstrated an association between an imaging-based diagnosis of NAFLD and an increased risk of coronary, cerebrovascular and peripheral vascular disease, and mortality. While some of these associations persist after adjusting for traditional cardiovascular risk factors, in others the association is lost. The latter, however, does not negate a role for the liver since, for example, atherogenic dyslipidemia is, in large part, liver-dependent. Numerous mechanisms have been proposed to explain the contribution of NAFLD to cardiovascular risk, including hepatic insulin resistance, atherogenic dyslipidemia, hepatic inflammation, and a prothrombotic milieu. In fatty liver, the accumulation of diacylglycerol and sphingolipids enhances hepatic insulin resistance. Likewise, hepatic cholesterol synthesis and very-low-density lipoprotein (VLDL) export are increased, catabolism of triglyceride-rich HDL is augmented, and LDL receptors are reduced, favoring the presence of cholesterol-rich VLDL remnants, small atherogenic LDL, and reduced HDL. In addition, hepatocytes, macrophages, and stellate cells are sensitized to endoand exotoxins, increasing inflammatory cytokines and promoting a systemic proinflammatory atherogenic state. Since the liver is the site of production of most coagulation factors, clotting factor abnormalities are expected in liver disease. In this issue, Verrijken et al. clarify this aspect of the NAFLD-metabolic syndrome-cardiovascular risk puzzle. In a large well-characterized group of NAFLD subjects (n 5 273), serum levels of five procoagulant factors (factors VII, VIII, XI, von Willebrand, and fibrinogen), two anticoagulant factors (protein C and AT III), activated protein C resistance (APC-R) and plasminogen activator inhibitor-1 (PAI-1) were quantified and platelet function assessed. In accordance with prior data, a correlation was observed between components of the metabolic syndrome and elevated fibrinogen, factor VIII, von Willebrand factor and PAI1, and decreased ATIII. Interestingly, PAI-1 was the only factor associated with hepatic histology, namely, steatosis, inflammation, ballooning, and fibrosis. In multivariate analysis, steatosis was an independent predictor of PAI-1 levels, after adjusting for metabolic factors. However, only 12% of its variance was explained by hepatic histology, probably a consequence of the ubiquitous expression of PAI-1. These findings align with prior reports in NAFLD where PAI-1 was elevated and in which the association persisted after adjusting for metabolic factors. Importantly, in a subgroup who had available liver tissue, PAI-1 expression was higher in those with nonalcoholic steatohepatitis (NASH) than those without, suggesting that the increased PAI-1 derives, at least partially, from liver. PAI-1 is a member of the serine protease inhibitor proteins family that inhibits tissue-type plasminogen Abbreviations: ECM, extracellular matrix; LPS, lipopolysaccharide; MMP, matrix metalloproteinase; PAI-1, plasminogen activator inhibitor-1; tPA, tissuetype plasminogen activator; uPA, urokinase plasminogen activator. Supported by a Robert W. Storr Bequest to the Sydney Medical Foundation and National Health and Medical Research Council (NHMRC 632630 and 1049857). Address reprint requests to: Professor Jacob George, Darcy Road Westmead NSW 2145, Australia. E-mail: jacob.george@sydney.edu.au; fax: 161-296357582. Copyright VC 2013 by the American Association for the Study of Liver Diseases. View this article online at wileyonlinelibrary.com. DOI 10.1002/hep.26588 Potential conflict of interest: Nothing to report.